Rising R&D Activities Coupled with Government Investments will Drive the Growth of the Global Incretin Based Drugs Market

The global incretin-based drugs market is anticipated to grow at a considerable CAGR of 5.5% during the forecast period (2022-2028). Increased research activity, government initiatives to promote disease awareness, and research grants are primary factors which are expected to fuel the global incretin-based drug market’s growth over the forecast period. Furthermore, rising government spending in R&D activities, as well as new product releases by numerous prominent companies, are expected to further propel the diabetes medicines market.

Browse the full report of "Global Incretin Based Drugs Market Size, Share & Trends Analysis Report by Drug Type (Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors), by Route of Administration (Oral and Injectable), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) Forecast (2022-2028)" at https://www.omrglobal.com/industry-reports/incretin-based-drugs-market

For instance, in October 2021, Glenmark launched drug in combination of various incretin based drug types including remogliflozin, vildagliptin, metformin fixed-dose combination (FDC) at an affordable cost for adults with type-2 diabetes. Among others, India is the first country to get access to this FDC drug. Glenmark had received an approval for the drug from the Drug Controller General of India (DCGI) for manufacturing and marketing back in September 2021. The new drug launched combines two or more active incretin based drugs in a single dosage form and can manage most of the pathophysiology in managing uncontrolled type-2 Diabetes. Further, in April 2019, Glenmark developed Remogliflozin, an oral anti-diabetic medicine that is deemed helpful in treating individuals with type-2 diabetes mellitus. Thus, increased product development in emerging countries along with rising healthcare expenditure will bolster the growth of the market.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Drug Type
• By Route of Administration
• By Distribution Channel

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- including AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Co., GlaxoSmithKline plc., Merck & Co., and others. 

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Incretin Based Drugs Market Report Segment

By Drug Type

• Glucagon-like Peptide-1 Receptor Agonists
• Dipeptidyl Peptidase-4 Inhibitor

By Route of Administration

• Oral
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Incretin Based Drugs Market Report Segment by Region

North America

• US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa